156 related articles for article (PubMed ID: 24668033)
1. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
De Jesus-Acosta A; Laheru D; Maitra A; Arcaroli J; Rudek MA; Dasari A; Blatchford PJ; Quackenbush K; Messersmith W
Invest New Drugs; 2014 Aug; 32(4):739-45. PubMed ID: 24668033
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla I; Wilson MK; Clarke BA; Hirte HW; Welch SA; Mackay HJ; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L; Liu G; Zhou C; Blattler C; Ivy SP; Oza AM
Gynecol Oncol; 2015 May; 137(2):216-22. PubMed ID: 25769658
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
Sardesai S; Badawi M; Mrozek E; Morgan E; Phelps M; Stephens J; Wei L; Kassem M; Ling Y; Lustberg M; Stover D; Williams N; Layman R; Reinbolt R; VanDeusen J; Cherian M; Grever M; Carson W; Ramaswamy B; Wesolowski R
Invest New Drugs; 2020 Oct; 38(5):1400-1410. PubMed ID: 31953695
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of RO4929097 in metastatic colorectal cancer.
Strosberg JR; Yeatman T; Weber J; Coppola D; Schell MJ; Han G; Almhanna K; Kim R; Valone T; Jump H; Sullivan D
Eur J Cancer; 2012 May; 48(7):997-1003. PubMed ID: 22445247
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL
Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
[TBL] [Abstract][Full Text] [Related]
8. A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
LoConte NK; Razak AR; Ivy P; Tevaarwerk A; Leverence R; Kolesar J; Siu L; Lubner SJ; Mulkerin DL; Schelman WR; Deming DA; Holen KD; Carmichael L; Eickhoff J; Liu G
Invest New Drugs; 2015 Feb; 33(1):169-76. PubMed ID: 25318436
[TBL] [Abstract][Full Text] [Related]
9. A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.
Gounder MM; Rosenbaum E; Wu N; Dickson MA; Sheikh TN; D'Angelo SP; Chi P; Keohan ML; Erinjeri JP; Antonescu CR; Agaram N; Hameed MR; Martindale M; Lefkowitz RA; Crago AM; Singer S; Tap WD; Takebe N; Qin LX; Schwartz GK
Clin Cancer Res; 2022 Apr; 28(8):1586-1594. PubMed ID: 35110418
[TBL] [Abstract][Full Text] [Related]
10. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
He W; Luistro L; Carvajal D; Smith M; Nevins T; Yin X; Cai J; Higgins B; Kolinsky K; Rizzo C; Packman K; Heimbrook D; Boylan JF
Mol Oncol; 2011 Jun; 5(3):292-301. PubMed ID: 21315665
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
Pan E; Supko JG; Kaley TJ; Butowski NA; Cloughesy T; Jung J; Desideri S; Grossman S; Ye X; Park DM
J Neurooncol; 2016 Dec; 130(3):571-579. PubMed ID: 27826680
[TBL] [Abstract][Full Text] [Related]
12. A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).
Means-Powell JA; Mayer IA; Ismail-Khan R; Del Valle L; Tonetti D; Abramson VG; Sanders MS; Lush RM; Sorrentino C; Majumder S; Miele L
Clin Breast Cancer; 2022 Feb; 22(2):103-114. PubMed ID: 34903452
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
[TBL] [Abstract][Full Text] [Related]
14. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Kolb EA; Gorlick R; Keir ST; Maris JM; Lock R; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 May; 58(5):815-8. PubMed ID: 22052798
[TBL] [Abstract][Full Text] [Related]
15. A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
Peereboom DM; Ye X; Mikkelsen T; Lesser GJ; Lieberman FS; Robins HI; Ahluwalia MS; Sloan AE; Grossman SA
Neurosurgery; 2021 Jan; 88(2):246-251. PubMed ID: 33027815
[TBL] [Abstract][Full Text] [Related]
16. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
Wang L; Dai G; Yang J; Wu W; Zhang W
Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
[TBL] [Abstract][Full Text] [Related]
17. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
Huynh C; Poliseno L; Segura MF; Medicherla R; Haimovic A; Menendez S; Shang S; Pavlick A; Shao Y; Darvishian F; Boylan JF; Osman I; Hernando E
PLoS One; 2011; 6(9):e25264. PubMed ID: 21980408
[TBL] [Abstract][Full Text] [Related]
18. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Luistro L; He W; Smith M; Packman K; Vilenchik M; Carvajal D; Roberts J; Cai J; Berkofsky-Fessler W; Hilton H; Linn M; Flohr A; Jakob-Røtne R; Jacobsen H; Glenn K; Heimbrook D; Boylan JF
Cancer Res; 2009 Oct; 69(19):7672-80. PubMed ID: 19773430
[TBL] [Abstract][Full Text] [Related]
19. Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.
Wu J; Lorusso PM; Matherly LH; Li J
Clin Cancer Res; 2012 Apr; 18(7):2066-79. PubMed ID: 22351688
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Sahebjam S; Bedard PL; Castonguay V; Chen Z; Reedijk M; Liu G; Cohen B; Zhang WJ; Clarke B; Zhang T; Kamel-Reid S; Chen H; Ivy SP; Razak AR; Oza AM; Chen EX; Hirte HW; McGarrity A; Wang L; Siu LL; Hotte SJ
Br J Cancer; 2013 Aug; 109(4):943-9. PubMed ID: 23868004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
